-
PBC Bridges The Gap: Launches Cannabis Banking Certification Amidst Rising Industry Demand
Friday, September 22, 2023 - 5:17pm | 510Read More...To cater to the increasing demand for specialized cannabis banking skills, PBC has unveiled its Cannabis Banking Certification Program. Historically, no universal training benchmark for cannabis banking compliance existed. This deficit impeded banks from employing adequately trained personnel,...
-
Top Cannabis Regulators Headline PBC Conference In 2023
Wednesday, April 26, 2023 - 3:08pm | 206Read More...PBC 2023 Conference to feature a keynote panel discussion with cannabis regulators from California, New York, Illinois, Oklahoma, and Massachusetts. PBC Co-Founder Peter Joukov will moderate a panel that includes: Nicole Elliott, Director, Department of Cannabis Control, California Tremaine Wright...
-
Will Intercept Stock Potential Be Blindsided By FDA Letter?
Friday, September 22, 2017 - 10:11am | 355Read More...Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) lost around one quarter of their value Thursday and another 7 percent early Friday morning in reaction to a concerning U.S. Food and Drug Administration letter sent to doctors regarding its liver treatment product called Ocaliva for the...
-
Morgan Stanley Downgrades Intercept Shares To Underweight, Cuts Target To $80
Friday, April 8, 2016 - 9:01am | 358Read More...Although Ocaliva in primary biliary cholangitis (PBC) has received the backing of an FDA panel, the panel did not endorse the drug for use in patients with advanced PBC, while recommending restrictions for use in non-responders and cirrhotics due to concerns regarding liver toxicity and safety....
-
Intercept Jumps 5%, Confirms FDA's Unanimous Decision To Recommend Accelerated Ocaliva Approval
Friday, April 8, 2016 - 7:29am | 240Read More...Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) were trading higher by 5 percent early Friday morning after the company announced the U.S. Food and Drug Administration's Gastrointestinal Drugs Advisory Committee voted to recommend Ocaliva. The committee voted unanimously at 17 to 0...
-
Wedbush Offers Probabilities For Upcoming Catalysts In Emerging Pharmas
Tuesday, December 8, 2015 - 9:29am | 850Read More...Liana Moussatos of Wedbush overviewed the emerging pharmaceuticals space and offered a scenario analysis of various potential catalysts. Moussatos has the highest degree of confidence on two upcoming catalysts for Relypsa Inc (NASDAQ: RLYP), one of which could see its stock move up or down by as...
